Scalper1 News
Biogen Idec wowed the medical community and investors with its much-anticipated Alzheimer’s disease drug results Friday, sending its stock to a new high before closing up 9.8% to 475.98. At a medical conference in France, Biogen (BIIB) reported the results of a phase 1b study in which 166 patients were divided into five groups, one a placebo group and the others taking different doses of Biogen’s drug candidate aducanumab, or Scalper1 News
Scalper1 News